- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05230550
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
November 23, 2023 updated by: Novo Nordisk A/S
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® A Multi-centre, Prospective, Open Label, Single-arm, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Sogroya® Therapy in Patients With Adult Growth Hormone Deficiency (AGHD) (Only Severe Case) Under Normal Clinical Practice Conditions in Japan
Participants are invited to take part in this study because they have AGHD (only severe case).
The purpose of this study is to assess long term safety and effectiveness of Sogroya® in patients with AGHD (only severe case) under normal clinical practice condition in Japan.
Participants will get Sogroya® as prescribed by the study doctor.
Participants will be in the study for about 2 to 5 years depending on when they take part in the study.
Participants will be asked to fill in the quality of life questionnaires.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan, 818 8502
- Novo Nordisk Investigational Site
-
Kumamoto, Japan, 862-0970
- Novo Nordisk Investigational Site
-
Kumamoto-shi, Kumamoto, Japan, 860-0811
- Novo Nordisk Investigational Site
-
Kyoto-shi, Kyoto, Japan, 606-8507
- Novo Nordisk Investigational Site
-
Nara, Japan, 633-0064
- Novo Nordisk Investigational Site
-
Oosakashi, Japan, 540-0003
- Novo Nordisk Investigational Site
-
Osaka, Japan, 572-0085
- Novo Nordisk Investigational Site
-
Osaka, Japan, 530-0013
- Novo Nordisk Investigational Site
-
Tokyo, Japan, 112-0001
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients with Adult Growth Hormone Deficiency (only severe case)
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
- The decision to initiate treatment with commercially available Sogroya® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study.
- Male or female, no age limitation
- Diagnosis of AGHD (only severe case)
- GH treatment naïve ("naïve patients") or "switched patients". "Naïve patients" are patients who are not exposed to any GH product to date or patients who were exposed to other GH product more than 180 days prior to registration. "Switched patients" are patients who is now treated by other GH product or patients who were exposed to other GH product within 180 days prior to registration.
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Patients with hypersensitivity to the active substance or to any of the excipients
- Patients with malignant tumor
- Female patients who are either pregnant or likely to be pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with AGHD (only severe case)
Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician.
The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.
|
Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as number
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Number of serious adverse events
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as number
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Number of serious adverse reactions
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as number
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Number of adverse reactions
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as number
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body fat mass
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as kilogram (kg)
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in body fat percentage
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as percent (%)
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in lean body mass
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as kg
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in cross-sectional total adipose tissue compartments (TAT)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as square centimeter (cm^2)
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in subcutaneous adipose tissue compartments (SAT)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as cm^2
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in visceral adipose tissue compartments (VAT)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as cm^2
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in Total cholesterol (T-Cho)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as milligrams per deciliter (mg/dL)
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in Low Density Lipoprotein-Cholesterol (LDL-Cho)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as mg/dL
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in High Density Lipoprotein-Cholesterol (HDL-Cho)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as mg/dL
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in triglyceride
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as mg/dL
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in Insulin-like Growth Factor I (IGF-I) standard deviation score (SDS)
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as standard deviation score
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in Quality of Life (QOL) Adult Hypopituitarism Questionnaire (AHQ) score
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as score range (0 = unfavorable to 6 = favorable)
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Change in QOL Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) score
Time Frame: From baseline (week 0) to end of study (up to 260 weeks)
|
Measured as score range (1 to 5; lower score indicates a better health state)
|
From baseline (week 0) to end of study (up to 260 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 3, 2022
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
January 28, 2022
First Submitted That Met QC Criteria
January 28, 2022
First Posted (Actual)
February 9, 2022
Study Record Updates
Last Update Posted (Actual)
November 27, 2023
Last Update Submitted That Met QC Criteria
November 23, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN8640-4638
- U1111-1247-5417 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Growth Hormone Deficiency
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Altus PharmaceuticalsCompleted
-
OPKO Health, Inc.CompletedAdult Growth Hormone DeficiencyCzechia, Hungary, Israel, Serbia, Slovakia, Slovenia
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
AEterna ZentarisCompletedDiagnosis of Adult Growth Hormone Deficiency (AGDH)United States
-
Merck KGaA, Darmstadt, GermanyCompletedAdult Growth Hormone Deficiency
-
University Hospital BirminghamRecruitingAdult Growth Hormone DeficiencyUnited Kingdom
Clinical Trials on Somapacitan
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedHealthy Volunteers | Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone DeficiencySlovakia
-
Novo Nordisk A/SRecruitingSGA, Turner Syndrome, Noonan Syndrome, ISSBelgium, Korea, Republic of, United States, Ireland, Malaysia, United Kingdom, Finland, France, Netherlands, Italy, Thailand, China, Japan, Portugal, Israel, Brazil, Greece, India, Mexico, Bulgaria, Serbia, Lithuania, Austria, Canada, C... and more
-
Novo Nordisk A/SRecruitingTurner Syndrome | Noonan Syndrome | SGA | ISSKorea, Republic of, Malaysia, Netherlands, Spain, Poland, United States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark, France, Germany, Japan, Sweden, United Kingdom
-
Novo Nordisk A/SActive, not recruitingShort Stature Children Born Small for Gestational Age (SGA)France, Russian Federation, United States, India, Spain, Estonia, Japan, Italy, Algeria, Austria, Hungary, Ireland, Israel, Latvia, Poland, Serbia, Thailand, Ukraine
-
Novo Nordisk A/SRecruitingGrowth Hormone Deficiency in ChildrenJapan